China-based vaccine specialist Clover Biopharmaceuticals, Ltd (HKG: 2197) announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase II/III clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.
Trial Results and Implications
There were no cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019. This indicates that the SCB-2019 vaccination reduced household transmission and that vaccinated household contacts also likely benefited from the protection provided by their own vaccination.
Global Distribution and Development
SCB-2019 has been developed with funding support from CEPI (the Coalition for Epidemic Preparedness Innovations) and will be eligible for sale and distribution globally through the Global Alliance for Vaccines and Immunisation’s (GAVI) COVAX mechanism. The protein vaccine was developed using Clover’s proprietary Trimer-Tag (protein trimerization) technology, a drug development platform which allows the production of novel, covalently-trimerized fusion proteins. Clover previously signed up with US-based Dynavax Technologies Corporation (NSDQ: DVAX) to provide Clover with the CpG 1018 vaccine adjuvant for use with the product.-Fineline Info & Tech
